MOTS-c: First Human Trial Started 2026 — What We Know

MOTS-c has one of the most interesting mechanistic stories in this field and, until this year, no human efficacy evidence whatsoever.

That changed in February 2026, when the first randomised placebo-controlled trial of MOTS-c in humans began recruiting. It will not report before 2027.

Everything currently claimed about MOTS-c in humans rests on mouse studies, cell work, and observational data about naturally occurring levels. None of that is the same as evidence that injecting it does anything.

What MOTS-c is

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a 16-amino-acid peptide encoded within mitochondrial DNA rather than in the cell nucleus, discovered in 2015.

That is genuinely novel biology. Mitochondria were long understood as power plants taking instructions from the nucleus. Mitochondrial-derived peptides like MOTS-c appear to signal in the other direction, and the family includes humanin and the six SHLP peptides.

In mice, administered MOTS-c activates AMPK, improves insulin sensitivity and glucose handling, reduces inflammatory markers, and improves exercise capacity. This is where the exercise mimetic framing comes from.

What is actually established in humans

One thing is well supported: MOTS-c is a real, exercise-responsive signal in the human body. Exercise increases MOTS-c levels in skeletal muscle and circulation, with levels rising during and immediately after exertion and returning toward baseline within hours.

Observational studies also show an inverse association between circulating MOTS-c and insulin resistance, meaning people with lower levels tend to have worse insulin sensitivity.

Both findings are about the body's own MOTS-c. Neither tells you what happens when you inject it. A molecule the body produces in response to exercise is not automatically useful as an injection, and the direction of that association is exactly the kind of question an interventional trial exists to answer.

The analog that reached humans first

Before this year, the closest human evidence came from CB4211, a modified MOTS-c analog developed by the biotech company CohBar. Its history is worth understanding because it is more informative than the headline it generated.

CB4211 went through a Phase 1a/1b trial for non-alcoholic steatohepatitis and obesity, enrolling 88 participants in total, with a Phase 1b portion of 20 people with obesity and fatty liver randomised to drug or placebo for four weeks.

In August 2021 CohBar announced positive topline results. The compound was well tolerated with no serious adverse events, and the only adverse events affecting more than one in ten participants were transient injection site reactions. Markers of liver injury fell, with ALT down 21% and AST down 28%, alongside a 6% reduction in glucose.

The detail usually omitted sits in CohBar's own release. On MRI measurement of liver fat content, the primary imaging outcome, the reduction was 5.03% on CB4211 against 4.88% on placebo. On the measure that most directly addressed the condition being treated, drug and placebo were effectively indistinguishable.

What happened next is equally telling. CohBar concluded the formulation used in Phase 1b was not suitable for further development and was unable to produce an improved one. In 2023 the company merged with Morphogenesis to become TuHURA Biosciences, which ended the programme. CB4211 never reached Phase 2.

The first trial of MOTS-c itself

In February 2026, MOTS-c entered human efficacy testing for the first time.

The study is registered as NCT07505745, under the acronym MOTS-MET, sponsored by Hudson Biotech. It is a Phase 2a randomised, double-blind, placebo-controlled trial evaluating whether 12 weeks of subcutaneous MOTS-c improves insulin sensitivity in adults with prediabetes and overweight or obesity, with around 120 planned participants. It began on 2 February 2026, is currently recruiting, and lists an estimated primary completion of February 2027 with full completion in 2028.

This is a properly designed study and a real step forward for the field.

Two notes of caution. A registration is a plan, not a result, and trials of this size at this stage frequently do not deliver what the preclinical work suggested. It is also worth knowing that the same sponsor registered several peptide trials at a single site within the same fortnight, covering MOTS-c, BPC-157, TB-500, GHK-Cu, Melanotan II, tesamorelin, tirzepatide and retatrutide. That is an unusual pattern and a reason to read the eventual results carefully rather than to discount them in advance.

Reported side effects

Because no completed human trial of MOTS-c exists, there is no established safety profile and no information on long-term use.

The United States Anti-Doping Agency has documented effects reported by people who purchased MOTS-c online, including increased heart rate and palpitations, injection site irritation, insomnia, local and generalised immune reactions, and fever. Self-reported effects from unregulated products are weak evidence, and they are the only human safety information that currently exists outside the analog study.

Regulatory position

Sport. MOTS-c is prohibited. Any athlete subject to anti-doping testing should treat it as disqualifying regardless of labelling.

United States. MOTS-c is not FDA-approved for anything. It was one of six peptides an FDA advisory committee recommended for the 503A compounding list in July 2026, a vote taken against the recommendation of the agency's own scientists, whose briefing materials cited the absence of clinical data on efficacy and safety. That recommendation is advisory, no rule has been published, and MOTS-c is not lawfully compoundable today.

United Kingdom. MOTS-C was among the compounds named when the MHRA opened its investigation into peptide clinics in April 2026.

Ireland and the EU. MOTS-c holds no marketing authorisation. Supplying an unauthorised medicinal product for human use is not permitted, and the HPRA is the competent authority.

Where this leaves things

MOTS-c is the clearest example in this field of a strong mechanism outrunning its evidence by a decade. The biology is real and genuinely novel. The human efficacy data does not yet exist.

The useful lesson is in CB4211. A company with capital, regulatory expertise and an optimised analog ran a proper trial, announced positive results, and quietly discovered the compound did not separate from placebo on the measure that mattered. Anyone reading preclinical enthusiasm should keep that sequence in mind.

The MOTS-MET readout in 2027 is the next real information. Until then, the honest position is that nobody knows.

About this article

This is a summary of published research, trial registrations and regulatory status. It is not medical advice and it is not legal advice, and nothing here is a recommendation to use MOTS-c.

If you have prediabetes or insulin resistance, the interventions with decades of trial evidence behind them are diet, physical activity and, where appropriate, metformin. Those are a conversation for your GP.